KOL Insight - Psoriatic Arthritis

This report provides a comprehensive analysis of the current and emerging treatment strategies for Psoriatic Arthritis (PsA), offering valuable insights into the evolving therapeutic landscape. It highlights the enduring role of TNF inhibitors and the rising preference for IL-17 and IL-23 inhibitors, particularly in cases with significant skin or ocular symptoms. Additionally, the report explores the shift from older therapies to newer IL-23 inhibitors, driven by their improved efficacy and ease of use. Through expert opinion from key opinion leaders (KOLs), this report offers a comprehensive overview of how these treatment shifts are shaping the future of PsA management.

Key Questions Answered:

• 1. What are the preferred current treatments for Psoriatic Arthritis (PsA)?
• 2. How do newer treatments like anti-IL17s and anti-IL23s compare to each other?
• 3. Where do oral therapies like JAK and TYK2 inhibitors stand in the current treatment landscape?
• 4. What patient factors most significantly influence PsA therapy choices?
• 5. How do payer pressures shape the decisions of key opinion leaders (KOLs)?
• 6. What impact will biosimilar anti-TNFs and JAK inhibitors have on the PsA treatment algorithm?
• 7. Which late-stage drug candidates are generating the most interest among KOLs?
• 8. What must pipeline drugs demonstrate to compete with market leaders?
• 9. What are the current gaps in PsA diagnosis and management?
• 10. How is the PsA treatment landscape expected to change in the next three to five years?

Key Brands:

Partial List of Participating Experts:

• Clinical Professor in the Department of Internal Medicine, UT Southwestern Medical Center, Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas, TX
• Co-Director, Clinical Rheumatology, Brigham and Women's Hospital and Professor of Medicine, Harvard Medical School, Boston, MA
• Clinical Associate Professor, Department of Medicine, Albert Einstein College of Medicine, NY
• Director of the Leeds NIHR Biomedical Research Centre, Professor of Rheumatology, University of Leeds, Leeds, UK
• Professor, Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC, Amsterdam, Netherlands
• Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments, Montpellier University, CHU Montpellier, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.